Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study - PubMed
6 hours ago
- #Vaccination
- #COVID-19
- #Multiple Sclerosis
- Study assesses antibody responses and COVID-19 outcomes in vaccinated people with multiple sclerosis (pwMS) on disease-modifying therapies.
- Nationwide Norwegian study (NevroVAX) includes 3559 pwMS and 449 healthy controls vaccinated with BNT162b2, mRNA-1273, or ChAdOx1.
- Seroconversion rates post-vaccination were lower in pwMS on anti-CD20 (43.0%) and S1PR modulators (48.4%).
- Seroconversion linked to reduced breakthrough infection risk (OR 0.67, 95% CI 0.58 to 0.78).
- Severe COVID-19 rare in pwMS: 1.6% hospitalized, 0.1% required non-invasive ventilation, no deaths reported.
- Findings support vaccination and tailored protective measures for immunomodulated populations despite impaired humoral responses.